Anti-tumour efficacy was compared to the anti-EGFR antibody cetuximab to exclude any EGFR blockade effects on tumour growth inhibition25 and determine the ability of a bispecific format to inhibit BRAF-mutated tumours by EGFR-specific T-cell activation. Here, BRAF is linked to neoplasm.